Formulated for rheumatoid arthritis to target inflammatory pathways and support joint preservation.
Mechanism of Action
Leflunomide is an immunomodulatory agent that inhibits dihydroorotate dehydrogenase, an enzyme in the de novo pyrimidine synthesis pathway. This reduces T-lymphocyte proliferation and anti-inflammatory activity.
Route of Administration
Oral
Onset Time
4–8 weeks
Duration
Weeks to months
Contraindications
Pregnancy, Severe hepatic impairment, Hypersensitivity to leflunomide
Information related to Arava is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
